ArticleBMC veterinary research2026
Glycyrrhiza polysaccharide inhibits feline infectious peritonitis virus infection screened by a recombinant virus expressing eGFP protein.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFeline infectious peritonitis (FIP) is a fatal infectious disease caused by feline infectious peritonitis virus (FIPV) which causes death of young cats less than 2 years old. Until now, few drugs are available for treatment of FIP. Here, we developed a modified FIPV expressing eGFP reporter gene by reverse genetics to evaluate the ability of Chinese herbal polysaccharides on inhibition of FIPV infection in Crandell-Rees feline kidney (CRFK) cells.
resultsThe results demonstrated that the recombinant FIPV could express eGFP reporter gene, replicated in the CRFK cells and grow in a similar way with wild-type FIPV. By using this recombinant FIPV, we found that glycyrrhiza polysaccharide (GPS) effectively inhibited FIPV when added at the same time with virus or post-infection in CRFK cells. Further studies revealed that GPS inhibited FIPV adsorption and replication, but did not affect FIPV internalization in CRFK cells.
conclusionsIn the current study, we successfully established a modified FIPV platform which supports high-throughput drug screening in vitro, and we found that GPS is a promising candidate for treating FIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.